VICTORIA, British Columbia & ROCKVILLE, Md. – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL), filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis (LN) to the European Medicines Agency (EMA)....
treatment News
ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. announced today the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases. Upon receiving FDA clearance to proceed with proposed research, Aurinia...
Melbourne, Australia – Cell Therapies Pty Ltd today announced the successful manufacture and release of the first clinical dose for the KOALA trial, a first-in-human study evaluating a novel CAR T-cell therapy for patients with relapsed or refractory multiple myeloma. The first patient has now been dosed with PMCC-COE-KMA, an investigational CAR...
Fairfield, N.J. — A two-day virtual event on March 15th and 16th will bring together more than 350 patients, caregivers, hepatologists, primary care providers, patient advocacy organizations and industry representatives all with one goal in mind—find solutions to improve health outcomes for all those suffering from rare autoimmune liver diseases....
Autologous hematopoietic stem cell transplant (HSCT) provides a long-term survival benefit, when compared with interferon (IFN)-alfa maintenance, in patients with advanced mantle cell lymphoma (MCL), according to research published in The Lancet Haematology.¹ Prior results from this study showed a progression-free survival (PFS) benefit with autologous HSCT, but it wasn’t...
THE WOODLANDS, TX — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking...
THE WOODLANDS, Texas — Autonomix Medical, Inc. a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced successful completion of an animal safety study evaluating the Company’s proprietary ablation technology. All safety inputs for the study were...
THE WOODLANDS, TX — Autonomix Medical, Inc. a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received authorization from the Uzbekistan Ethics Committee to open the clinical trial site for its proof-of-concept human...
THE WOODLANDS, TX — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its abstract titled, “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” has been selected as a Featured Abstract for...
DUBLIN, Ireland — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled “A New Dawn in the Management...